of the Drexel University School of Medicine. At that point, the patient underwent “surgical debulking” of his tumor. The pathology specimen confirmed the diagnosis of GBM and that the patient’s tumor ...

A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment ...

With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses ... The market is marked by a shift toward personalized medicine, where therapies are tailored to an ...

The US regulator has approved Tibsovo (ivosidenib) in combination with Bristol-Myers Squibb's chemotherapy Vidaza (azacitidine) as a first-line therapy for IDH1-mutated acute myeloid leukaemia ...

for IDH1-mutant acute myeloid leukaemia to the US market. It also shares commercial rights to BMS’ Idhifa (enasidenib), also for AML, and according to Bloomberg the two drugs should bring in ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

The researchers developed a UR-ddPCR assay for the IDH1 R132H mutation that accurately ... from the New York University Grossman School of Medicine, said in a statement. Several authors disclosed ...

It is indicated for patients with a susceptible IDH1 mutation, which is identified through an FDA-approved test. Currently, TIBSOVO is approved for the treatment of newly diagnosed acute myeloid ...

With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses ... The market is marked by a shift toward personalized medicine, where therapies are tailored to an ...